1 Barbara Davis Center for Diabetes, University of Colorado Denver , Aurora, Colorado.
2 Joslin Diabetes Center , Harvard Medical School, Boston, Massachusetts.
Diabetes Technol Ther. 2018 Jun;20(6):395-402. doi: 10.1089/dia.2018.0150. Epub 2018 Jun 14.
Frequent use of continuous glucose monitoring (CGM) systems is associated with improved glycemic outcomes in persons with diabetes, but the need for calibrations and sensor insertions are often barriers to adoption. In this study, we evaluated the performance of G6, a sixth-generation, factory-calibrated CGM system specified for 10-day wear.
The study enrolled participants of ages 6 years and up with type 1 diabetes or insulin-treated type 2 diabetes at 11 sites in the United States. Participation involved one sensor wear period of up to 10 days. Adults wore the system on the abdomen; youth of ages 6-17 years could choose to wear it on the abdomen or upper buttocks. Clinic sessions for frequent comparison with reference blood glucose measurements took place on days 1, 4-5, 7, and/or 10. Participants of ages 13 years and up underwent purposeful supervised glucose manipulation during in-clinic sessions. During the study, participants calibrated the systems once daily. However, analysis was performed on glucose values that were derived from reprocessed raw sensor data, independently of self-monitored blood glucose values used for calibration. Reprocessing used assigned sensor codes and a factory-calibration algorithm. Performance evaluation included the proportion of CGM values that were within ±20% of reference glucose values >100 mg/dL or within ±20 mg/dL of reference glucose values ≤100 mg/dL (%20/20), the analogous %15/15, and the mean absolute relative difference (MARD, expressed as a percentage) between temporally matched CGM and reference values.
Data from 262 study participants (21,569 matched CGM reference pairs) were analyzed. The overall %15/15, %20/20, and MARD were 82.4%, 92.3%, and 10.0%, respectively. Matched pairs from 134 adults and 128 youth of ages 6-17 years were similar with respect to %20/20 (92.4% and 91.9%) and MARD (9.9% and 10.1%). Overall %20/20 values on days 1 and 10 of sensor wear were 88.6% and 90.6%, respectively. The system's "Urgent Low Soon" (predictive of hypoglycemia within 20 min) hypoglycemia alert was correctly provided 84% of the time within 30 min before impending biochemical hypoglycemia (<70 mg/dL). The 10-day sensor survival rate was 87%.
The new factory-calibrated G6 real-time CGM system provides accurate readings for 10 days and removes several clinical barriers to broader CGM adoption.
频繁使用连续血糖监测(CGM)系统与改善糖尿病患者的血糖控制结果相关,但校准和传感器插入的需要往往是采用的障碍。在这项研究中,我们评估了 G6 的性能,G6 是一种第六代、工厂校准的 CGM 系统,指定可佩戴 10 天。
该研究招募了年龄在 6 岁及以上、患有 1 型糖尿病或接受胰岛素治疗的 2 型糖尿病的参与者,在美国 11 个地点进行。参与包括长达 10 天的传感器佩戴期。成年人将系统佩戴在腹部;年龄在 6-17 岁的青少年可以选择将其佩戴在腹部或上臀部。在第 1、4-5、7 和/或 10 天进行频繁与参考血糖测量比较的临床检查。年龄在 13 岁及以上的参与者在临床检查期间进行有目的的监督性血糖操作。在研究期间,参与者每天校准一次系统。然而,分析是基于从重新处理的原始传感器数据中得出的血糖值进行的,而与用于校准的自我监测血糖值无关。重新处理使用了分配的传感器代码和工厂校准算法。性能评估包括在参考血糖值 >100mg/dL 时,CGM 值在±20%范围内的比例>100mg/dL(%20/20),在参考血糖值≤100mg/dL 时,CGM 值在±20mg/dL 范围内的比例(%15/15),以及与参考值时间匹配的 CGM 和参考值之间的平均绝对相对差异(MARD,以百分比表示)。
分析了 262 名研究参与者(21569 对匹配的 CGM 参考对)的数据。总体%15/15、%20/20 和 MARD 分别为 82.4%、92.3%和 10.0%。年龄在 134 岁的成年人和 128 岁的 6-17 岁青少年的匹配对在%20/20(92.4%和 91.9%)和 MARD(9.9%和 10.1%)方面相似。佩戴传感器第 1 天和第 10 天的总体%20/20 值分别为 88.6%和 90.6%。系统的“紧急低血糖即将发生”(预测 20 分钟内发生低血糖)低血糖警报在即将发生生化性低血糖(<70mg/dL)前 30 分钟内,有 84%的时间正确提供了低血糖警报。10 天传感器存活率为 87%。
新型工厂校准的 G6 实时 CGM 系统可佩戴 10 天,并且消除了 CGM 广泛采用的一些临床障碍。